iCAD INC Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-06-30: Study NCT04349111; Company role Collaborator; Phase Not applicable; Status Withdrawn.
- 2021-11-02: Study NCT04681677; Company role Collaborator; Phase Phase 2; Status Terminated.
- 2013-11: Study NCT01851772; Company role Collaborator; Phase Not applicable; Status Completed.
- 2012-05-08: Study NCT01644669; Company role Collaborator; Phase Not applicable; Status Active not recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-06-30 | NCT04349111 An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | Collaborator Lead: Xoft, Inc. | Not applicable | Withdrawn | Invasive Ductal Carcinoma; Ductal Carcinoma In Situ | 0 | 2034-06-30 |
| 2021-11-02 | NCT04681677 Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab | Collaborator Lead: Xoft, Inc. | Phase 2 | Terminated | Glioblastoma; Recurrent Glioblastoma; GBM; Recurrent GBM | 12 | 2024-04-24 |
| 2013-11 | NCT01851772 Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer | Collaborator Lead: Xoft, Inc. | Not applicable | Completed Results posted | Cervical Cancer | 3 | 2015-06 |
| 2012-05-08 | NCT01644669 Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® | Collaborator Lead: Xoft, Inc. | Not applicable | Active not recruiting | Invasive Ductal Carcinoma; Ductal Carcinoma in Situ | 1,200 | 2029-12-31 |